Kate Rochlin

Company: IN8Bio

Job title: Chief Operating Officer

Seminars:

Activating the Potential of Gamma Delta T-Cells in Preclinical Models: A Next-Generation Strategy to Minimize CRS & Rethink TCE Safety in Autoimmunity 1:00 pm

How to selectively target powerful but rare cell-types such as gamma-delta T cells for target cell elimination, alternatives to CD3 Solving the scarcity issue: How to unlock the power of gamma delta T-cell engagers through novel design or mechanism to expand and activate gamma-delta T cells. Discussion of the shifting paradigm as we move from Oncology…Read more

day: Day Two

Panel Discussion: Investigating Preclinical Platforms for Autoimmune T-Cell Engagers From Human Relevant Assays to Regulatory Confidence 2:40 pm

For TCEs in autoimmunity, conventional preclinical tools, often adapted from oncology, fall short in capturing the inflammatory, chronic, and tissue-specific nature of disease. This panel will explore how to build assays that reflect real autoimmune biology, capture safety-relevant signals, and avoid reliance on transgenic animals. With human target expression and immune context being essential, developers…Read more

day: Day Two